LENZ Therapeutics Investor Relations Material
Latest events
Q2 2024
LENZ Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from LENZ Therapeutics Inc
Access all reports
LENZ Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on treating presbyopia, a common age-related condition that affects near vision. LENZ Therapeutics is currently advancing its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials. These products are aceclidine-based eye drops designed to restore near vision for individuals with presbyopia. The company is headquartered in Del Mar, California, and its shares are listed on the NASDAQ.
Latest articles
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Ticker symbol
LENZ
Country
🇺🇸 United States